Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
October 27, 2022 09:04 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
September 12, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage...
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
July 07, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
June 29, 2022 08:00 ET
|
Codiak BioSciences, Inc.
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak...
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
November 19, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma
October 22, 2021 13:39 ET
|
Privo Technologies
PEABODY, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining their lead asset PRV111 in...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
October 13, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
September 17, 2021 07:30 ET
|
TCR2 Therapeutics
- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall...
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
August 03, 2021 00:05 ET
|
Angion Biomedica Corp.
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
December 09, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMGTM) in healthy volunteers and COVID-19 patients with mild symptoms.STI-2020, a monoclonal antibody, has...